anti-doping testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
=== Combined malonic and methylmalonic aciduria (CMAMMA) === In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, mitochondrial fatty acid synthesis (mtFAS), which is the precursor reaction of lipoic acid biosynthesis, is impaired. The result is a reduced lipoylation degree of important mitochondrial enzymes, such as pyruvate dehydrogenase complex (PDC) and α-ketoglutarate dehydrogenase complex (α-KGDHC). Supplementation with lipoic acid does not restore mitochondrial function.
Ahmad (1990), head team physician of the New York Yankees and professor of Columbia University Vagelos College of Physicians and Surgeons Jennifer Ashton (1991), physician, author, host of lifestyle talk show The Revolution Virginia Cornish (1991), professor of chemistry at Columbia University and recipient of the 2009 Pfizer Award in Enzyme Chemistry Carl Marci (1991), neuroscientist and professor at Harvard Medical School Peter DiMaggio (1992), structural engineer, co-CEO of Thornton Tomasetti Damon Horowitz (1993), Google's in-house philosopher Chris Wiggins (1993), professor of applied mathematics at Columbia University, chief data scientist of The New York Times Rebecca Oppenheimer (1994), curator in astrophysics the American Museum of Natural History Demetre Daskalakis (1995), physician and gay health activist, White House National Monkeypox Response deputy coordinator Laura Kaufman (1997), chemist, professor at Columbia University Beth Willman (1998), astronomer at Haverford College Kate Brauman (2000), water scientist at the University of Minnesota, daughter of chemist John Isaiah Brauman Alex K.
A chronic wound is a wound that does not progress through the normal stages of wound healing—hemostasis, inflammation, proliferation, and remodeling—in a predictable and timely manner. Typically, wounds that do not heal within three months are classified as chronic. Chronic wounds may remain in the inflammatory phase due to factors like infection or bacterial burden, ischaemia, presence of necrotic tissue, improper moisture balance of wound site, or underlying diseases such as diabetes mellitus. In acute wounds, a regulated balance of pro-inflammatory cytokines (signalling molecules) and proteases (enzymes) prevent the degradation of the extracellular matrix (ECM) and collagen to ensure proper wound healing. In chronic wounds, there is excessive levels of inflammatory cytokines and proteases, leading to excessive degradation of the ECM and collagen. This disrupts tissue repair and impedes recovery, keeping the wound in a non-healing state. Chronic wounds may take years to heal or, in some cases, may never heal, causing significant physical and emotional stress for patients and placing a financial burden on healthcare systems. Acute and chronic wounds are part of a spectrum, with chronic wounds requiring prolonged and complex care compared to acute wounds.
Fei hua qing han (simplified Chinese: 飞花轻寒; traditional Chinese: 飛花輕寒; pinyin: Fēi huā qīng hán) is an apocryphal poem falsely attributed to Li Bai, an influential 8th-century Chinese poet. The poem attracted attention in the Chinese Internet community when some people deciphered a hidden message in it that says "Go to hell Japan, Koizumi must die" (日本去死, 小泉定亡). It was later revealed that the poem was written around 2003 to 2004. "Fei hua qing han" roughly means "a cold and flying chain of flowers".
Sources: en.wikipedia.org
== Emergencies == As the complete cross-matching process takes approximately 1 hour, it is not always used in emergencies. In the case of an emergency, a type-specific blood to which the recipient has no antibodies, can be requested. It is thought that this lifesaving measure is of more benefit than any risk of an antibody-mediated transfusion reaction. This type of blood has less risk of a serious transfusion reaction because it is both ABO compatible and Rhesus (Rh)-compatible. Universal donor blood, which is both type O and Rh negative, can be given if the recipient's blood group is not known, as may happen in an emergency. It is the policy of some institutions to reserve the releasing of O− blood only for female patients of childbearing age. This serves two purposes. First, it preserves the lower stock of O− blood and secondly, this eliminates the risk of O− negative mothers forming anti-D (Rh) antibodies from exposure to O+ blood. Anti-D (Rh) can cross the placenta during pregnancy and attack an unborn child's RBCs if they are D (Rh) positive causing haemolytic disease of the newborn. In an emergency, blood grouping can be done easily and quickly in 2 or 3 minutes in the laboratory on glass slides with appropriate reagents, by trained technical staff. This method depends on the presence or absence of agglutination (clumping of red blood cells), which can usually be visualized directly. Presence of agglutination indicates incompatibility. Occasionally a light microscope may be needed.
== External links == International Chemical Safety Card 0457 NIOSH Pocket Guide to Chemical Hazards. "#0226". National Institute for Occupational Safety and Health (NIOSH). Concise International Chemical Assessment Document 31: N,N-Dimethylformamide
===== Phase I ===== During phase I metabolism, mitragynine undergoes hydrolysis of the methylester group on C16 as well as o-demethylation of both methoxy groups on positions 9 and 17. Following this step, oxidation and reduction reactions convert aldehyde intermediates into alcohols and carboxylic acids. P450 metabolic enzymes are known to facilitate the phase I metabolism of mitragynine which reportedly has an inhibitory effect on multiple P450 enzymes, raising the possibility of adverse drug interactions.
The MMRV vaccine is a combination vaccine against measles, mumps, rubella (German measles), and varicella (chickenpox). It contains the combined measles vaccine, mumps vaccine, rubella vaccine, and varicella vaccine into a single injection. The MMRV vaccine has similar immunogenicity and overall safety profiles to the MMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age. Several companies supply MMRV vaccines. Proquad is marketed by Merck and was approved in 2005, for use in the United States for children aged twelve months of age through twelve years of age. Stand-alone virus measles, mumps, rubella, and varicella vaccines had been previously licensed in 1963, 1967, 1969, and 1995, respectively. An MMRV vaccine called Priorix Tetra by GlaxoSmithKline is available in some of the member states of the European Union.
Though the evidence linking antimicrobial usage in livestock to antimicrobial resistance is limited, the World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance strongly recommended the reduction of use of medically important antimicrobials in livestock. Additionally, the Advisory Group stated that such antimicrobials should be expressly prohibited for both growth promotion and disease prevention in food producing animals. By mapping antimicrobial consumption in livestock, it was predicted that in 228 countries there would be a total 67% increase in consumption of antibiotics by livestock by 2030. In some countries such as Brazil, Russia, India, China, and South Africa it is predicted that a 99% increase will occur. Several countries have restricted the use of antibiotics in livestock, including Canada, China, Japan, and the US. These restrictions are sometimes associated with a reduction of the prevalence of antimicrobial resistance in humans. In the United States the Veterinary Feed Directive went into practice in 2017 dictating that All medically important antibiotics to be used in feed or water for food animal species require a veterinary feed directive (VFD) or a prescription.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.